Presence on a human melanoma of multiple antigens recognized by autologous CTL - PubMed (original) (raw)
. 1989 Oct 15;44(4):634-40.
doi: 10.1002/ijc.2910440413.
Affiliations
- PMID: 2529220
- DOI: 10.1002/ijc.2910440413
Presence on a human melanoma of multiple antigens recognized by autologous CTL
B Van den Eynde et al. Int J Cancer. 1989.
Abstract
We derived from blood lymphocytes of a melanoma patient a large number of cytolytic T-cell clones directed against a cell line of the autologous tumor. Three distinct groups of antigens were recognized by these CTL on the autologous melanoma cells: group A consisted of stable antigens present on all sublines, whereas antigens B and C appeared unstable and were expressed by distinct sublines. In vitro immunoselections with various anti-A CTL clones were applied to the melanoma cells and variants resistant to 3 different CTL clones were obtained. These variants remained sensitive to other anti-A CTL clones, indicating that group A comprises at least 4 different antigens (D, E, F and A'). From a total of 76 CTL clones obtained from lymphocytes collected from the patient at various times, we found that 45 were anti-B, 17 were anti-C, 2 were anti-D, 9 were anti-E, 2 were anti-F and I was anti-A'. It is therefore likely that the 6 antigens identified by these CTL clones represent all or nearly all the transplantation antigens recognized by autologous CTL on this human melanoma.
Similar articles
- Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones.
Degiovanni G, Lahaye T, Hérin M, Hainaut P, Boon T. Degiovanni G, et al. Eur J Immunol. 1988 May;18(5):671-6. doi: 10.1002/eji.1830180503. Eur J Immunol. 1988. PMID: 2967757 - Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL).
Wölfel T, Hauer M, Klehmann E, Brichard V, Ackermann B, Knuth A, Boon T, Meyer Zum Büschenfelde KH. Wölfel T, et al. Int J Cancer. 1993 Sep 9;55(2):237-44. doi: 10.1002/ijc.2910550212. Int J Cancer. 1993. PMID: 7690346 - Genes coding for tumor antigens recognized by human cytolytic T lymphocytes.
Coulie PG, Weynants P, Lehmann F, Herman J, Brichard V, Wölfel T, Van Pel A, De Plaen E, Brasseur F, Boon T. Coulie PG, et al. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):104-9. doi: 10.1097/00002371-199308000-00004. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8280701 Review. - Antitumor immunity at work in a melanoma patient.
Coulie PG, Ikeda H, Baurain JF, Chiari R. Coulie PG, et al. Adv Cancer Res. 1999;76:213-42. doi: 10.1016/s0065-230x(08)60778-2. Adv Cancer Res. 1999. PMID: 10218103 Review.
Cited by
- TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer.
Karahan ZS, Aras M, Sütlü T. Karahan ZS, et al. Turk J Haematol. 2023 Feb 28;40(1):1-10. doi: 10.4274/tjh.galenos.2022.2022.0534. Epub 2023 Jan 31. Turk J Haematol. 2023. PMID: 36719099 Free PMC article. Review. - Melanoma vaccines: clinical status and immune endpoints.
Maurer DM, Butterfield LH, Vujanovic L. Maurer DM, et al. Melanoma Res. 2019 Apr;29(2):109-118. doi: 10.1097/CMR.0000000000000535. Melanoma Res. 2019. PMID: 30802228 Free PMC article. - Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy.
Xin G, Schauder DM, Zander R, Cui W. Xin G, et al. Immunotherapy. 2017 Sep;9(10):837-849. doi: 10.2217/imt-2017-0055. Immunotherapy. 2017. PMID: 28877635 Free PMC article. Review. - Applications of Immunogenomics to Cancer.
Liu XS, Mardis ER. Liu XS, et al. Cell. 2017 Feb 9;168(4):600-612. doi: 10.1016/j.cell.2017.01.014. Cell. 2017. PMID: 28187283 Free PMC article. Review. - The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Ward JP, Gubin MM, Schreiber RD. Ward JP, et al. Adv Immunol. 2016;130:25-74. doi: 10.1016/bs.ai.2016.01.001. Epub 2016 Feb 10. Adv Immunol. 2016. PMID: 26922999 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials